Patient-Reported Outcomes Following UGN-102 Treatment in Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: An Analysis of 3 Clinical Trials
In these analyses, patients with LG-IR-NMIBC receiving UGN-102 did not report worsening QoL, functioning, or symptom burden, supporting its use as a nonsurgical treatment for LG-IR-NMIBC.
Authors
- Tom Burke (ORCID: https://orcid.org/0000-0002-6563-1597)
- Michael J. Louie (ORCID: https://orcid.org/0000-0001-5464-8986)
- L. Veronica Lee
- Angela M. Stover (ORCID: https://orcid.org/0000-0003-0983-686X)
- Victoria Tsurutis
- Anagha Nadkarni
- Cheri L. Peyton (ORCID: https://orcid.org/0009-0008-8778-9759)
- Rahul Dhanda (ORCID: https://orcid.org/0000-0002-6941-3853)
- Max Kates (ORCID: https://orcid.org/0000-0003-1166-7225)
- Brent Burger
- Nikky Ugwuoke
Institutions
- University of North Carolina at Chapel Hill (US)
- University of Chester (GB)
- Johns Hopkins University (US)
- Princeton University (US)
- University of Alabama at Birmingham (US)
- Element Six (United Kingdom) (GB)
- UNC Lineberger Comprehensive Cancer Center
Publication Details
- Journal
- Urology Practice
- Published
- 2025-11-11
- DOI
- https://doi.org/10.1097/upj.0000000000000917
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00